-
201
Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmon...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
202
Supplementary Figure S4 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinom...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
203
Supplementary Figure S5 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinom...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
204
Supplementary Figure S6 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinom...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
205
Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
206
Supplementary Figure S3 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinom...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
207
Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
208
Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
209
Supplementary Figure S1 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinom...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
210
Supplementary Figure S2 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinom...
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
211
Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
212
Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
213
Supplementary Figure 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
214
Supplementary Figure 23. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
215
Supplementary Figure 26 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
216
Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
217
Supplementary Figure 11 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
218
Supplementary Figure 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
219
Supplementary Figure 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”
-
220
Supplementary Figure 27 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Έκδοση 2025Θέματα: “…Cancer Detection and Diagnosis…”